Developing New Generation Medicines for Depression, Pain, Social Anxiety and Other Central Nervous System (CNS) Diseases and Disorders with high unmet need

AV-101, our oral N-methyl-D-aspartate receptor glycine B (NMDAR GlyB) antagonist, belongs to a new generation of investigational medicines in neuropsychiatry known as glutamate receptor modulators having the potential to treat Major Depressive Disorder (MDD) faster than current FDA-approved antidepressants commonly known as SSRIs and SNRIs, which target the neurotransmitters serotonin and/or norepinephrine, respectively.

Learn About AV-101 AV-101 Mechanism of Action Video

Going Beyond Current Treatment Options

About us

Committed to Developing a New Generation of Oral Antidepressant

AV-101, our oral NMDAR GlyB (N-methyl-D-aspartate receptor glycine B) antagonist, belongs to a new generation of investigational medicines in neuropsychiatry known as glutamate receptor modulators with rapid-onset potential to treat Major Depressive Disorder (MDD) faster than currently available FDA-approved antidepressants such as SSRIs and SNRIs, which, if successful, take many weeks to months to generate antidepressant benefits.. AV-101 is in Phase 2 development, initially for the adjunctive treatment of MDD. in patients with an inadequate response to current antidepressants.

What Makes AV-101 Different?

Beyond Current Treatment Options

Focused on providing novel solutions for millions of depression patients with inadequate response to current FDA-approved antidepressants.

Learn More About Ketamine and AV-101

Experienced Leadership

Our experienced leadership team has a proven track record of developing innovative medicines to treat a wide range of CNS diseases and disorders.

Meet Our Team

Stock Information

View Detailed Stock Info
Nasdaq: VTGN Symbol
Price
Change
Volume
Day Range
52 Week Range

Corporate Presentation

Fact Sheet

For Investors

Email Updates

Be the first to receive news, events & updates Sign Up